# [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

> **NCT03724253** · PHASE2 · TERMINATED · sponsor: **Advanced Accelerator Applications** · enrollment: 19 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** [68Ga]-NeoBOMB1

## Key facts

- **NCT ID:** NCT03724253
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-03
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-07-05
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Recruitment was stopped before the target sample size was achieved.
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724253, "[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03724253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*